Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NWn0SFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS3NkBp M{jjcGROW09? MWHJR|UxRTBwMECwNFch|ryP MXGxO|k2PjB6MB?=
K562 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHXZmE4OiCq M4nTOWROW09? M1zGXmlEPTB;MD6wNFEh|ryP M3fZW|E4QTV4MEiw
M07e NFTWeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnMO|IhcA>? NGrCfoVFVVOR NGTHbGZKSzVyPUCuNFAyOiEQvF2= MYGxO|k2PjB6MB?=
ALL3 M{PNN2N6fG:2b4jpZ{BCe3OjeR?= NI\ROXcxNjIQvF2= NGfEe2c4OiCq NIj4bW1FVVOR NUjwPFBXUUN3ME2wMlAxODRizszN NH3lVpcyQTh6OUW0NC=>
CML M{H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvFNlAhdWmw NYLYRYM1TE2VTx?= NWHCRYh{UUN3ME2wMlAxOSEQvF2= NYfpbZhOOTl{MUmwNVY>
BA/F3 M3q2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS3NkBp MXnEUXNQ MV;JR|UxRTZwNUi5JO69VQ>? MViyN|A5QDZ2NB?=
BA/F3 M{\CWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnjTGM4OiCq NH25SWhFVVOR NUHPVJhnUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> M{XUSlI{ODh6NkS0
BA/F3 NW\ROpU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDne4FlPzJiaB?= M2PIZ2ROW09? NYjyeXF[UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= NF7qOY0zOzB6OE[0OC=>
BA/F3 NX;5UoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zTOlczKGh? MlvlSG1UVw>? MnnrTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MVSyN|A5QDZ2NB?=
BA/F3 NW\Yfo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD1XVJZPzJiaB?= MVPEUXNQ MYnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? NHjjNoEzOzNyMUewNy=>
BA/F3 M1;5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\MO|IhcA>? MnrGSG1UVw>? MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? MVKyN|MxOTdyMx?=
BA/F3 M4m1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;zO|IhcA>? NFrZcmhFVVOR M1TNTWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP Ml7iNlM{ODF5MEO=
BA/F3 M3XmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnrdZQ4OiCq MWnEUXNQ M2DsVWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1? Mn:wNlM{ODF5MEO=
BA/F3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGwO|IhcA>? M2[1eWROW09? NVnMbFA1UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= NVn3XJIzOjN|MEG3NFM>
BA/F3 NVywSXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jZZlczKGh? NYnodnRoTE2VTx?= NFjIdmJKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? NWP2[Vg6OjN|MEG3NFM>
BA/F3 NHvP[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrJO|IhcA>? NGTPV4VFVVOR M4HtXmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP NFrG[ZkzOzNyMUewNy=>
BA/F3 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK3NkBp MW\EUXNQ NYm3ZnlrUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? NFXpVJMzOzNyMUewNy=>
BA/F3 M4nkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe3RlU4OiCq NHPm[HVFVVOR MlfhTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NXrMUYR3OjN|MEG3NFM>
T cell M4\XeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:3NkBp M4Twb2ROW09? NVPvdHY1UW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? M1;pPFE4OTV2NUGy
WiDr MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq3NkBp NVjJcpZPTE2VTx?= MkPwTWM2OD1yLkC1NkDPxE1? NXjkd|FZOTV4MUW1NVI>
PC3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPjfGt2PzJiaB?= M1jD[2ROW09? M4\BN2lEPTB;MD6wNFk1KM7:TR?= M3XFOlE2PjF3NUGy
MDA-MB-231 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[3NkBp MXLEUXNQ NWDQbVJRUUN3ME2wMlAyOiEQvF2= MmDuNVU3OTV3MUK=
Hs578T NFHTd5lEgXSxdH;4bYMhSXO|YYm= MVG3NkBp NX7HNFl6TE2VTx?= NUfOPYlmT0l3ME2wMlA{KM7:TR?= MYCyOFAyPTN{Nx?=
HMEC M2f4OmN6fG:2b4jpZ{BCe3OjeR?= MUO3NkBp M2PxXWROW09? MmC2S2k2OD1zLkig{txO NXfaSHdlOjRyMUWzNlc>
DU145 M3POcmN6fG:2b4jpZ{BCe3OjeR?= MkDBO|IhcA>? MXLEUXNQ M3jDR2dKPTB;MD6xOkDPxE1? MYmyOFAyPTN{Nx?=
U251 M124cmN6fG:2b4jpZ{BCe3OjeR?= M4jzUlczKGh? MlLPSG1UVw>? NUHHdXNqT0l3ME2yMlgyKM7:TR?= MYmyOFAyPTN{Nx?=
NCI60 M1Pjd2N6fG:2b4jpZ{BCe3OjeR?= M3HFb|czKGh? NYriemxkTE2VTx?= NXy1S4FRT0l3ME21Mlch|ryP NWHqWXBTOjRyMUWzNlc>
MALME-3M NWrkZ2RnS3m2b4TvfIlkKEG|c3H5 MnnwO|IhcA>? NXuyWGpiTE2VTx?= MYPHTVUxRTZwNkGg{txO MVKyOFAyPTN{Nx?=
KM12 M{fSbWN6fG:2b4jpZ{BCe3OjeR?= NFPCbpc4OiCq NEjVbVdFVVOR M2jRRmdKPTB;Nz60OEDPxE1? MnfPNlQxOTV|Mke=
SW620 MnHRR5l1d3SxeHnjJGF{e2G7 NX6wVVdkPzJiaB?= NFPYOolFVVOR NHHOdGpIUTVyPUiuOFMh|ryP NWf1TJJNOjRyMUWzNlc>
RXF 393NL MoDwR5l1d3SxeHnjJGF{e2G7 NEWyXVc1KGSjeYO= MkTQSG1UVw>? MkXkTWM2OD1yLkCyNVch|ryP NYDhc3N2OjN{NUOwO|Q>
LXFA 983L M4PGUGN6fG:2b4jpZ{BCe3OjeR?= MoTNOEBl[Xm| MnrLSG1UVw>? NYPkdHlSUUN3ME2wMlA2PjVizszN M{\SS|I{OjV|MEe0
PRXF DU145 NYPEeY5vS3m2b4TvfIlkKEG|c3H5 MmnlOEBl[Xm| MkXYSG1UVw>? M1TlNmlEPTB;MD6wOlI{KM7:TR?= M13yclI{OjV|MEe0
PAXF 1657L MmjTR5l1d3SxeHnjJGF{e2G7 Mmf5OEBl[Xm| MUPEUXNQ MlPETWM2OD1yLkGyNUDPxE1? MlSwNlMzPTNyN{S=
CXF 1103L MY\DfZRwfG:6aXOgRZN{[Xl? M2r2cVQh\GG7cx?= NXj2T2JETE2VTx?= NFfySpBKSzVyPUSuN|Yh|ryP NWDyc5ZlOjN{NUOwO|Q>
GXF251L NFi1[|FEgXSxdH;4bYMhSXO|YYm= NYP2NlR6PCCmYYnz NGTLRopFVVOR MXPJR|UxRTJwMkWg{txO NYrXO2pQOjN{NUOwO|Q>
NCI-H23 NFn0U|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW3NkBp MlzOSG1UVw>? NEDYTmNKSzVyPUKuNlch|ryP NUfUWoE{OjN3MkGwNlA>
HCT116 NIWy[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[xSGo4OiCq NXm1bIdvTE2VTx?= MnvFTWM2OD1{LkOg{txO MWqyN|UzOTB{MB?=
MCF7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HZfVczKGh? MXrEUXNQ MlLxTWM2OD1{LkW3JO69VQ>? NIe1c2QzOzV{MUCyNC=>
NCI-H460 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lnc|czKGh? NUjYbmRqTE2VTx?= MV3JR|UxRThwOUmg{txO MYKyN|UzOTB{MB?=
DLD1 NITtW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3NkBp NVXZ[nE{TE2VTx?= MkjsTWM2OD12Lk[g{txO NVXxPFdEOjN3Nke5OlA>
NCI-H661 M{HCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SwRlczKGh? MlLhSG1UVw>? NGXFc5dKSzVyPUeuPEDPxE1? MXWyN|U3Pzl4MB?=
A549 NXPLdo41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWW3NkBp M370RmROW09? MVXJR|UxRThwMjFOwG0> MmXwNlM2Pjd7NkC=
U937 NGn6Wm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3NkBp NHmxNG5FVVOR NXzsNZFsUUN3ME2xNk4zKM7:TR?= NUDheZpUOjN3Nke5OlA>
HEK293 M3m5cmZ2dmO2aX;uJGF{e2G7 NHXxdFcyOMLizszN MmD2SG1UVw>? M4iwU2lv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN M4[wfFIzPzdyNkGw
HUVEC MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDCVWE5OC5zNdMg{txO NXfIfWsxPzJiaB?= MXHEUXNQ M4LvNWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> MXOyNlg2Ozl7Mx?=
HUVEC MUXGeY5kfGmxbjDBd5NigQ>? NXi5cmU6OTYEoN88US=> M3vndFczKGh? MmjESG1UVw>? M2PkfGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO M3SyUVIzQDV|OUmz
Plasmodium falciparum M3:wXWZ2dmO2aX;uJGF{e2G7 MYixNOKh|ryP M1HSU|E2KG2rbh?= M3rZRmROW09? NYXtdHpEUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP MoHUNlQ2PTB|M{C=
PC3 M2Dp[mZ2dmO2aX;uJGF{e2G7 NFXieY4xNjFizszN MXG1JIg> M4PXe2ROW09? NWOwW2JkUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N NHHNVVYyQTR4Mkm3OS=>
DU145 NHrMSpFHfW6ldHnvckBCe3OjeR?= NUe2RWJGOC5zIN88US=> M4nuSlUhcA>? M4nMOGROW09? MWTJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= NUHhZ25NOTl2NkK5O|U>
PC3 NVjBVlVrU2mwYYPlJGF{e2G7 NIfsWYwxNjFizszN MlH1OUBp M3LGZ2ROW09? MnXkTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= NYXvOlh3OTl2NkK5O|U>
DU145 M3;PcGtqdmG|ZTDBd5NigQ>? MWiwMlEh|ryP M{TISlUhcA>? NEjERXpFVVOR M4C3cGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NWDHWJV[OTl2NkK5O|U>
PC3 M4TuOWtqdmG|ZTDBd5NigQ>? NW\HOIg3OC5zIN88US=> NWGxSW5xPSCq MmDVSG1UVw>? MXvJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NGnTNGgyQTR4Mkm3OS=>
DU145 NHrjUHBMcW6jc3WgRZN{[Xl? NVLlXWFDOC5zIN88US=> MVG1JIg> M2nhZmROW09? NVzsd2ppUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= NUm5Um5FOTl2NkK5O|U>
Huh7 NYrYUZQ5SW62aY\pdoFtKEG|c3H5 NH\VOYQzNjVizszN MoH6OEBl[Xm| MknHSG1UVw>? NXnmSlhoUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN NWfHVYVPOTd|NkC2O|Y>
C6/36 MVfBcpRqfmm{YXygRZN{[Xl? MlP0Nk42KM7:TR?= MmO3OEBl[Xm| MVzEUXNQ MXfJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO NUnSVYQxOTd|NkC2O|Y>
U937 NYLzdoRnTnWwY4Tpc44hSXO|YYm= NInQbHIyKM7:TR?= NY[3eGFiOSCq Mn[1SG1UVw>? M3v3d3Jm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| Mlq0NVc3QDRyOUm=
U937 MnHISpVv[3Srb36gRZN{[Xl? NH65TlkyKM7:TR?= MmDvNUBp NXSzdnV6TE2VTx?= NYWzNJI3WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NWPNOFROOTd4OESwPVk>
murine mast cell MWnGeY5kfGmxbjDBd5NigQ>? MkXBNUDPxE1? MkHINlQhcA>? M2nyWGROW09? NVnZdJZqUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= M1rjUVE4Pjh2MEm5
BV-173 NUHCdHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHMTWM2OD1yLkCwNFAxODFyOTFOwG0> MmmxV2FPT0WU
K-562 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfGUm9KSzVyPUCuNFAxODByMk[2JO69VQ>? Mo\IV2FPT0WU
BL-70 NWHsNIhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH6dopnUUN3ME2wMlAxODByMEiyNkDPxE1? NVfMUoZ1W0GQR1XS
EM-2 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMECwNFAyODhizszN NUTJb5RLW0GQR1XS
LAMA-84 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPxWoZnUUN3ME2wMlAxODByM{KxJO69VQ>? NVfTPJNUW0GQR1XS
MEG-01 M2PXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4doFuUUN3ME2wMlAxODByOUig{txO NXjJZ5ZbW0GQR1XS
EoL-1-cell MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76TVJVUUN3ME2wMlAxODBzM{Gg{txO MVTTRW5ITVJ?
CTV-1 M{TsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PISGlEPTB;MD6wNFAxPDB2IN88US=> Mo[1V2FPT0WU
TE-15 NWXHdJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPZNY5JUUN3ME2wMlAxPTh7IN88US=> MmfIV2FPT0WU
NOS-1 M{D1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO2TWM2OD1yLkCwOlE{KM7:TR?= NUHOR5RXW0GQR1XS
D-336MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;abmlEPTB;MD6wNFY{KM7:TR?= NIfn[5FUSU6JRWK=
LB1047-RCC M3PiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P1dmlEPTB;MD6wNFk5QSEQvF2= NYDzdoFqW0GQR1XS
LB996-RCC NV7UZ5hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17mPWlEPTB;MD6wNFk6OSEQvF2= MoTMV2FPT0WU
SW982 NFfGNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEGxNVUh|ryP MWLTRW5ITVJ?
TK10 NIPVUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOzTYhKSzVyPUCuNFEyPzRizszN MXfTRW5ITVJ?
A704 NFrtVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf2VHpXUUN3ME2wMlAyPDlzIN88US=> NGC3RXFUSU6JRWK=
TE-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHnPFZ{UUN3ME2wMlAyPTd4IN88US=> MVHTRW5ITVJ?
DOHH-2 M2\r[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3[plZUUN3ME2wMlAyPzF7IN88US=> NIO1cJFUSU6JRWK=
HOP-62 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPoUm92UUN3ME2wMlAyQDN2IN88US=> MXrTRW5ITVJ?
TE-12 NFi4TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjZXm9NUUN3ME2wMlAyQDZzIN88US=> MWDTRW5ITVJ?
KGN M3fkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L3c2lEPTB;MD6wNVk1OiEQvF2= M3uzdnNCVkeHUh?=
NCI-H1648 M37CR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;TTWM2OD1yLkCyNFEyKM7:TR?= M1niZ3NCVkeHUh?=
OS-RC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7yTWM2OD1yLkCyNFMh|ryP NYjLTJpZW0GQR1XS
GB-1 NIjqO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fDT2lEPTB;MD6wNlE2PyEQvF2= MXTTRW5ITVJ?
RXF393 NWLS[3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorrTWM2OD1yLkCyN|U4KM7:TR?= MVzTRW5ITVJ?
LC-2-ad MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEK1PFYh|ryP M4jHbnNCVkeHUh?=
KS-1 NHzOfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX4dVZoUUN3ME2wMlAzPzNizszN NXjrVm9SW0GQR1XS
ETK-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\aOIpKSzVyPUCuNFI5OzJizszN MVHTRW5ITVJ?
SW954 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDPOFFKSzVyPUCuNFI6OjdizszN MWfTRW5ITVJ?
Becker M4TyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e0OGlEPTB;MD6wN|AxOyEQvF2= MVXTRW5ITVJ?
MZ1-PC M2rrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LTOGlEPTB;MD6wN|EyQSEQvF2= M3n5c3NCVkeHUh?=
ES6 NIryXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMEOxPVMh|ryP M4XXeHNCVkeHUh?=
KURAMOCHI MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm0UYJKSzVyPUCuNFM1QDdizszN MmW3V2FPT0WU
CGTH-W-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy0[mpTUUN3ME2wMlA{PTR6IN88US=> M1nNVHNCVkeHUh?=
VA-ES-BJ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NViwUJR1UUN3ME2wMlA{QTB{IN88US=> MmL3V2FPT0WU
LXF-289 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M361dGlEPTB;MD6wN|k2PiEQvF2= MUPTRW5ITVJ?
MPP-89 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTNfoQyUUN3ME2wMlA1ODR7IN88US=> M2jzbXNCVkeHUh?=
SW872 NXnLUnJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHPTWM2OD1yLkC0NVYyKM7:TR?= NWHNeFNiW0GQR1XS
SNB75 NYH1OnZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hsd2lEPTB;MD6wOFQ{PSEQvF2= MW\TRW5ITVJ?
PSN1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r1UWlEPTB;MD6wOFQ4PCEQvF2= M1O2Z3NCVkeHUh?=
LB831-BLC NYX5WItqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLTenY{UUN3ME2wMlA1PjB7IN88US=> M2r1NHNCVkeHUh?=
MFH-ino MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTsOZZKSzVyPUCuNFQ4OjRizszN MWnTRW5ITVJ?
TGBC24TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXvTWM2OD1yLkC0O|YyKM7:TR?= MWnTRW5ITVJ?
A388 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfreGRiUUN3ME2wMlA2ODl3IN88US=> NFTESYZUSU6JRWK=
BB30-HNC NYf4S4w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXt[nlKSzVyPUCuNFU1OzdizszN M17sSHNCVkeHUh?=
GI-ME-N MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;VXWtQUUN3ME2wMlA3OTF6IN88US=> NIi5R|ZUSU6JRWK=
TGBC1TKB Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwME[xOlQh|ryP NFvrPYRUSU6JRWK=
TE-10 NVK1O5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwME[zOVch|ryP NX64eYdKW0GQR1XS
A498 NWHQd4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV70N2lXUUN3ME2wMlA4Ojh2IN88US=> NF\aR4lUSU6JRWK=
TE-11 NIG4N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor2TWM2OD1yLkC3PFU5KM7:TR?= NG\xdXRUSU6JRWK=
BB65-RCC NGP3eG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEiyNlch|ryP NWLkb5p[W0GQR1XS
C2BBe1 NXHTd5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XqcWlEPTB;MD6wPFMxQCEQvF2= MWjTRW5ITVJ?
NCI-H747 NGHae|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEizOlIh|ryP NYPQWJd{W0GQR1XS
IST-MES1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrWVJZWUUN3ME2wMlA5PTV{IN88US=> NY\ES2xJW0GQR1XS
KALS-1 M13HUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDRdJJyUUN3ME2wMlA6PDlizszN M2PnNXNCVkeHUh?=
GCIY MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0PGlEPTB;MD6wPVY2PiEQvF2= M371[XNCVkeHUh?=
RL95-2 NILERW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL0TWM2OD1yLkGwN|gh|ryP NV3HWZR1W0GQR1XS
TE-1 M2fwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvSXJVKSzVyPUCuNVA2PCEQvF2= NWLRbYZpW0GQR1XS
NCI-H1355 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\zTWM2OD1yLkGxNFI5KM7:TR?= M1WxS3NCVkeHUh?=
SW962 NGfnO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DtSmlEPTB;MD6xNVI6OiEQvF2= NHXRepZUSU6JRWK=
KLE M2rPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrkWnJKSzVyPUCuNVE{OTdizszN NVjp[HNKW0GQR1XS
MC116 NVrIO5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vIfmlEPTB;MD6xNVQyKM7:TR?= NVfHRlQ{W0GQR1XS
NMC-G1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv3TWM2OD1yLkGxOlA3KM7:TR?= M4[5eXNCVkeHUh?=
KU812 NFX6[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fBeWlEPTB;MD6xNVg5OyEQvF2= M4G4cHNCVkeHUh?=
COLO-829 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GwRWlEPTB;MD6xNlIyOyEQvF2= MY\TRW5ITVJ?
NTERA-S-cl-D1 M1vvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTmXG5{UUN3ME2wMlEzOjh|IN88US=> MV;TRW5ITVJ?
IST-MEL1 M3TvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn31TWM2OD1yLkGzOFUh|ryP MWfTRW5ITVJ?
MLMA NYDvVY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zVWWlEPTB;MD6xOFA{OiEQvF2= MVXTRW5ITVJ?
LS-123 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XGTGlEPTB;MD6xOFA3PCEQvF2= M4rlTHNCVkeHUh?=
LB2518-MEL NEDNT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTGTWM2OD1yLkG0NVYzKM7:TR?= Mk\JV2FPT0WU
NB69 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMUS0N|Yh|ryP NUG0R3hxW0GQR1XS
8-MG-BA M{DpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\UcGlEPTB;MD6xOVQ2QCEQvF2= M{HrfHNCVkeHUh?=
K5 NEL0OGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DUW2lEPTB;MD6xOlQ5QSEQvF2= M1TjVHNCVkeHUh?=
KINGS-1 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jybmlEPTB;MD6xOlY3PiEQvF2= MnfGV2FPT0WU
SF268 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zzWWlEPTB;MD6xO|QxPCEQvF2= NXi1XmpEW0GQR1XS
PF-382 NXHITGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX0eXBXUUN3ME2wMlE4Pjd6IN88US=> NGrIUXJUSU6JRWK=
SH-4 M4rBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDRPHhKSzVyPUCuNVg1OTNizszN MYHTRW5ITVJ?
NALM-6 NIriem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMUmyPVUh|ryP M1vMNnNCVkeHUh?=
CP66-MEL M{[1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUm1N|Eh|ryP Ml:4V2FPT0WU
697 M{fxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33TfGlEPTB;MD6xPVk5PyEQvF2= M{PTeHNCVkeHUh?=
CP67-MEL MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj4dmNNUUN3ME2wMlIxPDh6IN88US=> NIfJc4hUSU6JRWK=
DSH1 NVT6TI5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMkSwNFEh|ryP MkfXV2FPT0WU
HCE-4 NVLkdY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;RTWM2OD1yLkK2OFM6KM7:TR?= NYDsT3dUW0GQR1XS
MZ2-MEL MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTjNlFRUUN3ME2wMlI5PTN5IN88US=> MYHTRW5ITVJ?
BL-41 M3X3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH1OJFvUUN3ME2wMlI6OTJ|IN88US=> NWPsO21oW0GQR1XS
HUTU-80 NHvmTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH71PYFKSzVyPUCuN|E1OiEQvF2= NF\aeW9USU6JRWK=
LOXIMVI NIrxSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuycWlsUUN3ME2wMlMyPTB|IN88US=> MmixV2FPT0WU
no-10 NFewfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PiRWlEPTB;MD6zNVk{OSEQvF2= MVPTRW5ITVJ?
KARPAS-422 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:2WWx3UUN3ME2wMlM{QTl5IN88US=> MkfTV2FPT0WU
SW684 NWTUR5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPaTWM2OD1yLkO0PVgh|ryP NELueHlUSU6JRWK=
SF126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPKenhKSzVyPUCuN|U1OSEQvF2= NVfqbHR{W0GQR1XS
D-263MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDlTWM2OD1yLkO2NlI1KM7:TR?= M3\ERnNCVkeHUh?=
OVCAR-4 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\weHRIUUN3ME2wMlM4PDN|IN88US=> MnH3V2FPT0WU
BB49-HNC NFrMdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj5eWdKSzVyPUCuN|g2QTlizszN NVjtdY53W0GQR1XS
ONS-76 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHTTWM2OD1yLkSyPVUyKM7:TR?= M1n3VHNCVkeHUh?=
MZ7-mel M4ftPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;DTWM2OD1yLkS3PVEyKM7:TR?= MnLVV2FPT0WU
RCC10RGB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryTWM2OD1yLkS5NVEh|ryP Mnu1V2FPT0WU
BOKU M1n1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOy[GRKSzVyPUCuOFkyOzNizszN NFnFT3VUSU6JRWK=
no-11 NUHNfVRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrqZ3JoUUN3ME2wMlUxOjJ6IN88US=> M4\u[XNCVkeHUh?=
IST-SL2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLXTWM2OD1yLkWwN|AzKM7:TR?= Mlq2V2FPT0WU
RKO NVe3NllIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNUK5OlYh|ryP M1jaN3NCVkeHUh?=
HT-144 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH1UmdKSzVyPUCuOVM3ODlizszN NHHOWmpUSU6JRWK=
NCI-H446 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjRXJZ7UUN3ME2wMlYzPzZizszN MXHTRW5ITVJ?
QIMR-WIL M3TxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6bllKSzVyPUCuO|A3OjlizszN MnjGV2FPT0WU
MHH-PREB-1 NWHlPHVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXUTWM2OD1yLke0OFY6KM7:TR?= NWLzTmJGW0GQR1XS
EW-16 NYHNOHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnFUJpuUUN3ME2wMlc3OTd6IN88US=> NEfZNolUSU6JRWK=
EW-24 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnnfYFFUUN3ME2wMlc5OTZ3IN88US=> NXj4TIxiW0GQR1XS
LB373-MEL-D NV;GcZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXOTWM2OD1yLkiyOVA5KM7:TR?= MXTTRW5ITVJ?
TE-9 M1;ZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rkUmlEPTB;MD64O|U{OiEQvF2= NIqyOVdUSU6JRWK=
A3-KAW M3nud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KzUGlEPTB;MD65PFQ2OiEQvF2= NGDqd2VUSU6JRWK=
A101D M1nEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSxTWM2OD1zLkCzNFQ{KM7:TR?= NVPGfHJHW0GQR1XS
OCUB-M NXXtXGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2OD1zLkC0OFEzKM7:TR?= NWj0fJZ6W0GQR1XS
ES4 NEPOenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknqTWM2OD1zLkC1NVQ2KM7:TR?= NXLaRZFUW0GQR1XS
TE-6 NEfhZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITRPGZKSzVyPUGuNlEzOjZizszN MnTtV2FPT0WU
D-502MG M1fZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xy[WlEPTB;MT6yN|M4PiEQvF2= NXz2SVR2W0GQR1XS
KNS-42 NG\1T3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHCN3hKSzVyPUGuNlQ1OTJizszN MWXTRW5ITVJ?
SNU-C2B NHLhPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\uTmlEPTB;MT6zNFU5QSEQvF2= NXj4OGlMW0GQR1XS
NCI-H1838 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfCcGJ3UUN3ME2xMlMxPzN|IN88US=> M2rRSHNCVkeHUh?=
NKM-1 NGDoZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4[ZJKSzVyPUGuN|A5PTlizszN MoLxV2FPT0WU
GI-1 M1\NT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn4RlRYUUN3ME2xMlM3OjJizszN MnrLV2FPT0WU
NB5 M{jJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7sfnlKSzVyPUGuN|k5OjdizszN M{PZfnNCVkeHUh?=
CAS-1 NG[yWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;KTWM2OD1zLkSwPVkzKM7:TR?= MmW2V2FPT0WU
HCE-T NGe5O3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnFTWM2OD1zLkW2O|E1KM7:TR?= NVjyTppLW0GQR1XS
SBC-1 M{m3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TKdmlEPTB;MT61O|k5PCEQvF2= MYHTRW5ITVJ?
JiyoyeP-2003 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrUSWlrUUN3ME2xMlc{PDZ4IN88US=> M1LzZnNCVkeHUh?=
TE-5 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPwXZlKSzVyPUGuO|kyOzlizszN MYjTRW5ITVJ?
CAN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOx[HlKSzVyPUGuPFIzPTJizszN MXHTRW5ITVJ?
SK-UT-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESwOI5KSzVyPUKuNVY3QTNizszN MV3TRW5ITVJ?
JVM-2 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHTTWM2OD1{LkO2Nlg1KM7:TR?= M{TQbHNCVkeHUh?=
LB771-HNC M3jiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3QenB1UUN3ME2yMlU4PTVzIN88US=> MlnXV2FPT0WU
NCCIT M1Tqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ncGRwUUN3ME2yMlg3PjF4IN88US=> MXzTRW5ITVJ?
NCI-H2126 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HCW2lEPTB;Mj64O|U2OiEQvF2= NEP5R25USU6JRWK=
Calu-6 M33Ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW2TWM2OD1|LkC1O|QyKM7:TR?= M1;CfnNCVkeHUh?=
SK-LMS-1 NEPTZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P4XWlEPTB;Mz6xNVg5PiEQvF2= MkfKV2FPT0WU
ARH-77 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTYPY97UUN3ME2zMlQ3QTF3IN88US=> MX\TRW5ITVJ?
NB17 NEnmbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT4eJZUUUN3ME2zMlY{QDR5IN88US=> NIXYTldUSU6JRWK=
A253 NF61NmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\wfmlEPTB;Mz63N|I1PiEQvF2= MVvTRW5ITVJ?
OPM-2 M2L2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTSbmlyUUN3ME20MlI4Pjh3IN88US=> M2js[3NCVkeHUh?=
MV-4-11 M2n4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[4TWM2OD12LkO2OFU1KM7:TR?= M1POS3NCVkeHUh?=
SR NXfNOGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwNEm5OVQh|ryP MlnKV2FPT0WU
KG-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;iR2lEPTB;ND62NFg1PSEQvF2= M131bnNCVkeHUh?=
OCI-AML2 NX7jUJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHDTWM2OD13Lki2NVU1KM7:TR?= M136NXNCVkeHUh?=
D-247MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TSOWlEPTB;Nj6xNlUyQSEQvF2= MVjTRW5ITVJ?
DJM-1 NEPwU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDTWM2OD14LkS4OVU5KM7:TR?= MUDTRW5ITVJ?
RPMI-6666 NUDacXFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDBWZRKSzVyPUeuNlcxPjdizszN NIPvNHhUSU6JRWK=
KARPAS-45 NGPBem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW4W2NKSzVyPUeuOVE3PzFizszN NFfFcGlUSU6JRWK=
LP-1 NFL1S3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTdwNUS3PFIh|ryP NFWxRnJUSU6JRWK=
RS4-11 M4f1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdwNkW3PFch|ryP MWXTRW5ITVJ?
DU-4475 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1ZmlEPTB;OD6yNVY2OiEQvF2= MlW0V2FPT0WU
MONO-MAC-6 M1nnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRThwMkewOlYh|ryP MnzrV2FPT0WU
NCI-SNU-16 NXzNUWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRThwNU[xNlgh|ryP NUCzdIRlW0GQR1XS
SJSA-1 NULnSGFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;WTWM2OD16LkeyPFA2KM7:TR?= NV7U[IttW0GQR1XS
MMAC-SF M1XXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TUfWlEPTB;OD63PVMxPyEQvF2= NETrdJdUSU6JRWK=
SK-NEP-1 M4HEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i5S2lEPTB;OD64PVE2PSEQvF2= M3HaZnNCVkeHUh?=
J-RT3-T3-5 NVHvSop4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\lUG86UUN3ME24Mlk3PTJ7IN88US=> M{HObHNCVkeHUh?=
SKM-1 NEfrR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX4U4pbUUN3ME25MlAyPzN2IN88US=> NGXK[YNUSU6JRWK=
LB2241-RCC M2Hod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH5e21KSzVyPUmuNFIxOTJizszN MUPTRW5ITVJ?
SIG-M5 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfke|NsUUN3ME25MlAzPDl|IN88US=> M3vFcXNCVkeHUh?=
EVSA-T M{Cxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULO[mpJUUN3ME25MlI4Pzl|IN88US=> MnrDV2FPT0WU
GT3TKB M1HFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD17LkO1OVQ3KM7:TR?= NG[0UVNUSU6JRWK=
NB6 M1PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTXdYl3UUN3ME25MlkzOjV7IN88US=> M13JfnNCVkeHUh?=
EHEB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFyLkC2OVYh|ryP Mn3TV2FPT0WU
HEL MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFyLkS3O|Yh|ryP MmLnV2FPT0WU
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDaXppIUUN3ME2xNE44QTN6IN88US=> NH\zOm1USU6JRWK=
TGW NWexfG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTETWM2OD1zMT6yPFI5KM7:TR?= MVjTRW5ITVJ?
BC-3 NH2wd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXRcWhTUUN3ME2xNk4yOTN6IN88US=> Mlj5V2FPT0WU
IA-LM NIrLW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXTTWM2OD1zMj60OFQ2KM7:TR?= MV3TRW5ITVJ?
UACC-257 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e3[2lEPTB;MUKuPVE6QCEQvF2= NXOyWm9MW0GQR1XS
KP-N-YS M3rlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHYTWM2OD1zMj65Nlg{KM7:TR?= MoDUV2FPT0WU
Raji NXv0bId[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3dGlEPTB;MUOuO|Q6PyEQvF2= MkGzV2FPT0WU
SF539 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nsb2lEPTB;MUOuPFU2PyEQvF2= M{TEUXNCVkeHUh?=
DMS-153 NV\0UVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXaZoJKSzVyPUG0MlAxOjhizszN MkjVV2FPT0WU
L-540 NXPnSol7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF3LkC2O|Ih|ryP MW\TRW5ITVJ?
MN-60 M4\KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\DNoVnUUN3ME2xOU4yQTd7IN88US=> Mlm3V2FPT0WU
RPMI-8866 NY\sRVU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD6e|hEUUN3ME2xO{41PDV2IN88US=> Mn20V2FPT0WU
NCI-H510A M{\Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF7LkO5O|Mh|ryP MUnTRW5ITVJ?
NB13 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInlSVZKSzVyPUG5MlQ5PzdizszN MmL5V2FPT0WU
HAL-01 M4LncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXPSYp2UUN3ME2xPU44PTR|IN88US=> M{TrRXNCVkeHUh?=
NCI-H720 NEf0RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\nTWM2OD1{MD6yO|M{KM7:TR?= Ml2yV2FPT0WU
REH M{n3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX2b|ZWUUN3ME2yNE43OzV5IN88US=> NFm1SWpUSU6JRWK=
KNS-81-FD MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHUTWM2OD1{Mz6xOFYh|ryP NUDRfIM{W0GQR1XS
HC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjUTWM2OD1{ND61OVUyKM7:TR?= MVXTRW5ITVJ?
NCI-H2141 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmexTWM2OD1{ND63O|U1KM7:TR?= MoLyV2FPT0WU
MOLT-4 MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD1{Nj62O|U{KM7:TR?= NIDRTG9USU6JRWK=
OMC-1 NUHRNmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzoTWM2OD1{Nz6xOFIzKM7:TR?= MWTTRW5ITVJ?
LC-1F NVPDN2J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2NGlEPTB;MkeuN|I1PSEQvF2= MoK3V2FPT0WU
NCI-H1304 NHHRN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HQXmlEPTB;MkiuNVYzQCEQvF2= MkH2V2FPT0WU
BC-1 NVLlXIZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ6Lk[1NUDPxE1? MYLTRW5ITVJ?
NCI-H64 NVntWJZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJ7Lk[yOVMh|ryP MUjTRW5ITVJ?
MOLT-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ7Lk[yPVIh|ryP NFfNNmdUSU6JRWK=
U-87-MG NVTWTIJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTNyLke2OkDPxE1? MXjTRW5ITVJ?
GAK MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvaTWM2OD1|MT6yOlg3KM7:TR?= NYPzRplCW0GQR1XS
ES8 NEnDfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XITmlEPTB;M{KuNVI2OiEQvF2= M3L4[XNCVkeHUh?=
HCC1599 NY[4d3FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljZTWM2OD1|Mj6zN|I2KM7:TR?= MmLUV2FPT0WU
EB-3 NVHy[VhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHWSZhKSzVyPUO0MlMyOTdizszN MXLTRW5ITVJ?
HCC1187 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN3LkiwOVIh|ryP MYDTRW5ITVJ?
SK-PN-DW NUTCfm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPS[3pKSzVyPUO2MlE6PDNizszN NYTsVJd6W0GQR1XS
JVM-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftUmlEPTB;M{euNlM{QCEQvF2= MmSxV2FPT0WU
HCC2157 NVTQTGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnSfFZKSzVyPUO3Mlk6PDZizszN NXXjcGtrW0GQR1XS
A4-Fuk MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHRTWM2OD1|OD6xNFA6KM7:TR?= NFn4VVRUSU6JRWK=
COR-L279 NVvoUXpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHQfXhKSzVyPUSwMlI5PTFizszN MmrhV2FPT0WU
DEL M4n1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHsTWM2OD12MT65NFg3KM7:TR?= MX;TRW5ITVJ?
NCI-H1395 NHix[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3KTWM2OD12Mj6wNVY{KM7:TR?= NUj0N2VjW0GQR1XS
MHH-NB-11 NIfpR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTrTWM2OD12Mz6wPFE5KM7:TR?= M1X3T3NCVkeHUh?=
NCI-H2107 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO4cJVKSzVyPUSzMlQ5PDZizszN MX3TRW5ITVJ?
NEC8 NX;SVIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTzTWM2OD12ND6zN|Yh|ryP MXnTRW5ITVJ?
COLO-684 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;wVmlEPTB;NE[uNlI2QCEQvF2= NH32fXVUSU6JRWK=
LS-411N MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jP[GlEPTB;NEiuOFc1QCEQvF2= MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay
+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research
+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT02815059 Not yet recruiting Acute Lymphoblastic Leukemia University of Utah|Janssen, LP August 2016 Phase 1
NCT02819804 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia Northwestern University|National Cancer Institute (NCI) July 2016 Phase 1
NCT02848131 Recruiting Chronic Kidney Disease Mayo Clinic July 2016 Phase 2
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto June 2016 Phase 2
NCT02776878 Recruiting Gastrointestinal Stromal Tumor Beijing Cancer Hospital May 2016 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID